In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CVRx to raise $93mm in Series G and enters $20mm term loan

Executive Summary

CVRx Inc. (cardiovascular devices) raised $57.7mm through its Series G financing led by Johnson & Johnson Development Corp., which was joined by other returning shareholders New Enterprise Associates and Ysios BioFund, and first-time backers Gilde Healthcare Partners, Action Potential Venture Capital , and Windham Venture Partners. In addition, $35.3mm has already been subscribed by the investors and will close upon CVRx achieving an operational milestone. The company will use the proceeds to complete its Phase III clinical trial of its Barostim neo implantable device for chronic heart failure. CVRx also entered a term loan with Oxford Finance to help repay an existing loan.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies